By Fineline Cube 
Danaher Corporation (NYSE: DHR) reported fourth‑quarter and full‑year 2025 earnings with global revenues rising 3% year‑on‑year (YOY) to $24.6 billion , while core revenues grew 2% YOY . Net profit reached $3.6 billion . The company launched several innovative products across its life sciences and diagnostics segments during the year.
Financial Performance Summary
| Metric | Result |
|---|---|
| Q4/FY 2025 Revenue | $24.6 billion |
| YOY Growth | +3% |
| Core Revenue Growth | +2% YOY |
| Net Profit | $3.6 billion |
| Key Growth Drivers | Bioprocessing, diagnostics menu expansion, mass spectrometry |
Product Innovations & Segment Highlights
Life Sciences
- Cytiva: Expanded Xcellerex X-platform bioreactor portfolio with 500L and 2000L models, reducing time and cost of biologics manufacturing
- SCIEX: Introduced ZenoTOF 8600 high-resolution mass spectrometer, accelerating drug development cycles
Diagnostics
- Beckman Coulter Diagnostics: Significantly expanded test menu for DxI 9000 immunoassay platform, achieving notable advancements in neurodegenerative disease testing
- Cepheid: Received FDA approval for Xpert GI Panel, a rapid multiplex PCR test detecting 11 common gastrointestinal pathogens from a single patient sample
Forward‑Looking Statements
This brief contains forward‑looking statements regarding Danaher’s future revenue growth, product development timelines, and commercial prospects. Actual results may differ due to market conditions, competitive dynamics, and regulatory approvals.-Fineline Info & Tech